Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Candel Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 20 | 23 | +3 |
| Shares | 6.95M | 6.67M | −277.4K (−4.0%) |
| Value | $54.4M | $34.0M | −$20.4M (−37.5%) |
New holders (5)
Institutions that held Candel Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bridgeway Capital Management, LLC | 75,000 | $382.0K | 0.01% |
| Kestra Advisory Services, LLC | 12,500 | $64.0K | 0.00% |
| Empirical Asset Management, LLC | 12,000 | $61.0K | 0.06% |
| Quent Capital, LLC | 182 | $1.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 54 | $0 | 0.00% |
Sold out (2)
Institutions that held Candel Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Woodline Partners LP | 100,000 | $782.0K |
| Millennium Management LLC | 13,106 | $102.0K |